LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis
BG Zeiher, J Steingrub, PF Laterre… - Critical care …, 2005 - journals.lww.com
Objective: Group IIA secretory phospholipase A 2 (sPLA2-IIA), released during inflammation,
is increased in severe sepsis, and plasma levels are inversely related to survival. In a
previous study, a selective inhibitor of sPLA2-IIA (LY315920NA/S-5920) was well tolerated
and appeared to improve survival in a subgroup of patients who received the drug within 24
hrs of first sepsis-induced organ failure. This study was designed to determine whether
improvement in survival could be confirmed in a larger patient population meeting the …
is increased in severe sepsis, and plasma levels are inversely related to survival. In a
previous study, a selective inhibitor of sPLA2-IIA (LY315920NA/S-5920) was well tolerated
and appeared to improve survival in a subgroup of patients who received the drug within 24
hrs of first sepsis-induced organ failure. This study was designed to determine whether
improvement in survival could be confirmed in a larger patient population meeting the …